Epstein-Barr Virus BRRF1 Induces Butyrophilin 2A1 in Nasopharyngeal Carcinoma NPC43 Cells Via the IL-22/JAK3-STAT3 Pathway

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2025 Jan 8

PMID 39769218

Authors

Yue Liu

Ka Sin Lui

Zuodong Ye

Luo Chen

Allen Ka Loon Cheung

Affiliations

Soon will be listed here.

Abstract

Epstein-Barr virus is highly associated with nasopharyngeal carcinoma (NPC) with genes expressed for tumor transformation or maintenance of viral latency, but there are certain genes that can modulate immune molecules. Butyrophilin 2A1 (BTN2A1) is an important activating protein for presenting phosphoantigens for recognition by Vγ9Vδ2 T cells to achieve antitumor activities. We have previously shown that Vγ9Vδ2 T cells achieve efficacy against NPC when BTN2A1 and BTN3A1 are upregulated by stimulating EBV gene expression, particularly LMP1. While BTN3A1 can be induced by the LMP1-mediated IFN-γ/JNK/NLRC5 pathway, the viral gene that can regulate BTN2A1 remains elusive. We showed that BTN2A1 expression is directly mediated by EBV BRRF1, which can trigger the BTN2A1 promoter and downstream JAK3-STAT3 pathway in NPC43 cells, as shown by RNA-seq data and verified via inhibitor experiments. Furthermore, BRRF1 downregulated IL-22 binding protein (IL-22RA2) to complement the EBNA1-targeting probe (P)-induced IL-22 expression. Therefore, this study elucidated a new mechanism of stimulating BTN2A1 expression in NPC cells via the EBV gene BRRF1. The JAK3-STAT3 pathway could act in concordance with IL-22 to enhance the expression of BTN2A1, which likely leads to increased tumor cell killing by Vγ9Vδ2 T cells for enhanced potential as immunotherapy against the cancer.

References

Zheng Y, Valdez P, Danilenko D, Hu Y, Sa S, Gong Q . Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med. 2008; 14(3):282-9. DOI: 10.1038/nm1720. View

Yao Y, Yang G, Lu G, Ye J, Cui L, Zeng Z . Th22 Cells/IL-22 Serves as a Protumor Regulator to Drive Poor Prognosis through the JAK-STAT3/MAPK/AKT Signaling Pathway in Non-Small-Cell Lung Cancer. J Immunol Res. 2022; 2022:8071234. PMC: 9167127. DOI: 10.1155/2022/8071234. View

Yoshida M, Watanabe T, Narita Y, Sato Y, Goshima F, Kimura H . The Epstein-Barr Virus BRRF1 Gene Is Dispensable for Viral Replication in HEK293 cells and Transformation. Sci Rep. 2017; 7(1):6044. PMC: 5519699. DOI: 10.1038/s41598-017-06413-7. View

Bian B, Fanale D, Dusetti N, Roque J, Pastor S, Chretien A . Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncoimmunology. 2019; 8(4):e1561120. PMC: 6422385. DOI: 10.1080/2162402X.2018.1561120. View

Chang S, Lo Y, Chua H, Chiu H, Tsai S, Chen J . Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expression. J Virol. 2008; 82(15):7745-51. PMC: 2493335. DOI: 10.1128/JVI.02717-07. View

Li Y, Chung G, Lui V, To K, Ma B, Chow C . Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat Commun. 2017; 8:14121. PMC: 5253631. DOI: 10.1038/ncomms14121. View

Hui K, Lam B, Ho D, Tsao S, Chiang A . Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Mol Cancer Ther. 2013; 12(5):747-58. DOI: 10.1158/1535-7163.MCT-12-0811. View

Bradley J, Pober J . Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene. 2001; 20(44):6482-91. DOI: 10.1038/sj.onc.1204788. View

Chyuan I, Chu C, Hsu P . Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. Cancers (Basel). 2021; 13(6). PMC: 7998672. DOI: 10.3390/cancers13061188. View

10.

Wilson J, Manet E, Gruffat H, Busson P, Blondel M, Fahraeus R . EBNA1: Oncogenic Activity, Immune Evasion and Biochemical Functions Provide Targets for Novel Therapeutic Strategies against Epstein-Barr Virus- Associated Cancers. Cancers (Basel). 2018; 10(4). PMC: 5923364. DOI: 10.3390/cancers10040109. View

11.

Martin B, Hirota K, Cua D, Stockinger B, Veldhoen M . Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity. 2009; 31(2):321-30. DOI: 10.1016/j.immuni.2009.06.020. View

12.

Jiang L, Lung H, Huang T, Lan R, Zha S, Chan L . Reactivation of Epstein-Barr virus by a dual-responsive fluorescent EBNA1-targeting agent with Zn-chelating function. Proc Natl Acad Sci U S A. 2019; 116(52):26614-26624. PMC: 6936348. DOI: 10.1073/pnas.1915372116. View

13.

Sabat R, Ouyang W, Wolk K . Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014; 13(1):21-38. DOI: 10.1038/nrd4176. View

14.

Aras S, Singh G, Johnston K, Foster T, Aiyar A . Zinc coordination is required for and regulates transcription activation by Epstein-Barr nuclear antigen 1. PLoS Pathog. 2009; 5(6):e1000469. PMC: 2690687. DOI: 10.1371/journal.ppat.1000469. View

15.

Hagemeier S, Barlow E, Kleman A, Kenney S . The Epstein-Barr virus BRRF1 protein, Na, induces lytic infection in a TRAF2- and p53-dependent manner. J Virol. 2011; 85(9):4318-29. PMC: 3126225. DOI: 10.1128/JVI.01856-10. View

16.

Renaud S, Lefebvre A, Mordon S, Morales O, Delhem N . Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma. Int J Mol Sci. 2020; 21(12). PMC: 7352617. DOI: 10.3390/ijms21124292. View

17.

Govindan R, Ding L, Griffith M, Subramanian J, Dees N, Kanchi K . Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012; 150(6):1121-34. PMC: 3656590. DOI: 10.1016/j.cell.2012.08.024. View

18.

Munz C . Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol. 2019; 17(11):691-700. DOI: 10.1038/s41579-019-0249-7. View

19.

Fang C, Lee C, Wu C, Chang Y, Yu S, Chou S . Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. Int J Cancer. 2009; 124(9):2016-25. DOI: 10.1002/ijc.24179. View

20.

Hong G, Delecluse H, Gruffat H, Morrison T, Feng W, Sergeant A . The BRRF1 early gene of Epstein-Barr virus encodes a transcription factor that enhances induction of lytic infection by BRLF1. J Virol. 2004; 78(10):4983-92. PMC: 400377. DOI: 10.1128/jvi.78.10.4983-4992.2004. View